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Purpose
Treatment options for sJIA are limited. Excessive IL-6 pro-
duction has been implicated in several manifestations of
this disease. In a previous Japanese study, TCZ, an IL-6
receptor inhibitor, improved arthritis and systemic features
of patients with refractory sJIA. We present efficacy and
safety of TCZ in patients with active sJIA who were trea-
ted for ≥52 wks in the global, 3-part, 5-yr, phase 3, multi-
center TENDER study.
Methods
Patients (N=112) 2–17 yrs with active sJIA for ≥6 mo and
inadequate response to corticosteroids (CS) and NSAIDs
were randomized 2:1 to TCZ (8 mg/kg if body weight
≥30 kg; 12 mg/kg if <30 kg) or placebo (control) every 2
wks for 12 wks in part 1; all patients received open-label
TCZ at 8 or 12 mg/kg per body weight in part 2. Patients
who escaped to open-label TCZ in part 1 also entered
part 2. Oral CS tapering was permitted at wks 6 and 8 in
part 1 and in the open-label extension in patients with
ACR70 response, ESR <20 mm/h, and no fever. Efficacy
data are presented for patients who had reached wk 52 of
TCZ treatment by May 10, 2010 (n=88); safety data
through May 10, 2010 are presented for all patients
(n=112). Wk 52 baseline was the first TCZ dose; part 1
placebo patients were re-baselined when they escaped or
entered part 2.
Results
Proportions of TCZ patients who achieved JIA ACR30 +
absence of fever or JIA ACR70/90 progressively
improved from wk 12 to wk 52 (Table). Number (mean
±SD) of joints with active arthritis or with limited range
of motion decreased from 19.8±15.7 and 19.8±15.6,
respectively, at baseline to 3.0±7.0 and 7.5±11.7, respec-
tively, at wk 52, with 45% of patients having 0 active
joints. At baseline, 55% of patients (n=62) had fever
(temperature ≥37.5°C in the preceding 14 days), while at
wk 52 only 9% (n=8) had fever. From baseline to wk 52,
improvement in the scores was: CHAQ-DI from 1.7±0.9
to 0.7±0.8; physician global assessment VAS from 64.9
±22.3 to 9.7±12.8, and patient/parent global assessment
VAS from 58.7±24.4 to 12.6±18.5. There was a marked
reduction in CS dose from 0.30±0.20 mg/kg/d at base-
line to 0.06±0.08 at wk 52, with 48% having discontin-
ued CS. There were 33 serious AEs (SAEs) in 25
patients; 12 SAEs were considered related (remote, pos-
sible, or probable) to TCZ (SAE rate: 0.23/patient year
[PY] in part 1, 0.25/PY in part 2). Among the 15 serious
infections, 6 were considered related to TCZ; all
resolved and none led to study discontinuation. Twelve
patients withdrew: 4 because of AEs; 4 because of insuf-
ficient response, 3 withdrew consent or did not return,
and 1 died of a suspected tension pneumothorax unre-
lated to treatment.
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Conclusion
Year 1 results from this first global phase 3 study
demonstrate that TCZ is highly effective and generally
well tolerated in patients with sJIA.
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Table 1
Wk 12 Wk 52
Control TCZ TCZ
JIA ACR responses, n (%) (N=37) (N=75) (N=88)
ACR30 = absence of fever 9 (24) 64 (85) 77 (88)
ACR70 3 (8) 53 (71) 78 (89)
ACR90 2 (5) 28 (37) 57 (65)
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